Back to search results

AU-011 for Eye Cancer Metastases to the Choroid

This study is testing a new treatment called AU-011 for people with eye cancer that has spread to the choroid (the layer of blood vessels in the eye). The treatment involves injecting AU-011 into the space around the choroid using a special device, followed by laser treatment. Researchers want to see how safe AU-011 is and how well people tolerate it. They will also measure if the treatment shrinks the eye tumors. You may be able to join if you are 18 or older, have a confirmed diagnosis of cancer that has spread to your choroid, and have at least one tumor in your study eye. The study plans to enroll 24 participants, but its current recruitment status is unclear.

Study design
This is an open-label study, meaning both you and your doctors will know which treatment you are receiving. It will test different doses of AU-011 and plans to enroll 24 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study will measure changes in your tumor size 4 weeks after you finish treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06643884

Suprachoroidal Administration in Subjects With Metastases to the Choroid

Recruiting
PHASE2Ages 18+InterventionalTreatment
Aura Biosciences
~24 participants
Updated 2026-03-13 on ClinicalTrials.gov
What's tested:AU-011SCS MicroinjectorLaser

At a glance

Recruiting sites
7 of 10 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change from baseline in choroidal tumor thickness on B-scan ultrasonography (B-scan) 4 weeks after completion of treatment.
Measured over 4 weeks after completion of treatment
+1 more outcome measured

Conditions

Eye Cancer
Primary Cancer

Explore related trials

Metastatic Malignant Neoplasm in the ChoroidSolid Neoplasm

NCT06643884

Where you'd take part

This study runs at 10 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Bascom Palmer Eye Institute

    Miami, Floridano site contact published

    Recruiting

  • Byers Eye Institute at Stanford University

    Palo Alto, Californiano site contact published

    Recruiting

  • Cleveland Clinic, Cole Eye Institute

    Cleveland, Ohiono site contact published

    Not yet recruiting

  • Kellogg Eye Center

    Ann Arbor, Michiganno site contact published

    Recruiting

  • Massachusetts Eye and Ear

    Boston, Massachusettsno site contact published

    Recruiting

  • Mayo Clinic

    Rochester, Minnesotano site contact published

    Not yet recruiting

  • Retina Consultants of Texas

    Bellaire, Texasno site contact published

    Recruiting

  • Shields and Shields, PC

    Philadelphia, Pennsylvaniano site contact published

    Not yet recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Medical Monitor · STUDY_DIRECTOR · Aura Biosciences

Who to contact

Medical Monitor
[email protected]
617-500-8864
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Have a clinical diagnosis of Metastases to the Choroid, from a histopathologically or cytologically confirmed tumor.
Have at least one Metastases to the Choroid in the study eye

Exclusion

Active ocular infection or disease.
Must not have evidence of a primary tumor or metastatic lesion in the brain requiring treatment with radiation therapy per the primary treating oncologist's assessment.
Must not be planning or expecting to switch/add systemic antineoplastic therapies during treatment

What this trial measures

  • Change from baseline in choroidal tumor thickness on B-scan ultrasonography (B-scan) 4 weeks after completion of treatment.4 weeks after completion of treatment

    B-Scan Ultrasonography

  • Change from baseline in choroidal tumor largest basal diameter (LBD) on fundus photos 4 weeks after completion of treatment.4 weeks after completion of treatment

    Fundus photos